{"filing":{"accession_number":"0001104659-26-091674","cik":"0000894158","ticker":"TOVX","company_name":"Theriva Biologics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tm2622359d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm"},"events":[{"id":25412,"run_id":23065,"accession_number":"0001104659-26-091674","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Theriva Biologics announced dosing of the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent dosing of VCN-01 in metastatic pancreatic cancer, representing a material clinical development milestone for the company's lead candidate.","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26235,"accession_number":"0001104659-26-091674","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a clinical development milestone—dosing of the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent dosing of VCN-01 in metastatic pancreatic cancer. This is an operational/strategic event reflecting progress in the company's lead clinical-stage candidate. While material to investors assessing the company's pipeline advancement and regulatory pathway, it does not fit the specific event types (e.g., earnings, M\u0026A, impairment, litigation) and is best classified as an operational milestone rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:55.142266+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26237,"accession_number":"0001104659-26-091674","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces a clinical development milestone—dosing of the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent dosing of VCN-01 in metastatic PDAC patients. This is a material operational/strategic event for a clinical-stage biotech company, as it represents progress toward a potential pivotal Phase 3 trial and reflects advancement of the company's lead candidate. The event does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named types, but is clearly material to investors assessing the company's clinical pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:55.142266+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26235,"accession_number":"0001104659-26-091674","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a clinical development milestone—dosing of the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent dosing of VCN-01 in metastatic pancreatic cancer. This is an operational/strategic event reflecting progress in the company's lead clinical-stage candidate. While material to investors assessing the company's pipeline advancement and regulatory pathway, it does not fit the specific event types (e.g., earnings, M\u0026A, impairment, litigation) and is best classified as an operational milestone rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:55.142266+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-06"},{"id":26237,"accession_number":"0001104659-26-091674","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces a clinical development milestone—dosing of the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent dosing of VCN-01 in metastatic PDAC patients. This is a material operational/strategic event for a clinical-stage biotech company, as it represents progress toward a potential pivotal Phase 3 trial and reflects advancement of the company's lead candidate. The event does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named types, but is clearly material to investors assessing the company's clinical pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:55.142266+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-06"}]}